Table 2.
Strategy-dual checkpoint inhibitor combinations.
| Intervention | Strategy | Date (last updated) | Status | Patient population | Phase | Study design | ClinicalTrials.gov identifier |
|---|---|---|---|---|---|---|---|
| Nivolumab + Ipilimumab | PD-1 inhibitor, CTLA-4 inhibitor | 8 December 2015 | Recruiting | Advanced metastatic pancreatic tumor | I/II | Arm N- Nivolumab monotherapy. Arm N-I – Nivolumab + Ipilimumab combination therapy |
NCT01928394 |
| Tremelimumab + MEDI4736 | CTLA-4 inhibitor, PD-L1 inhibitor | 5 December 2015 | Recruiting | Unresectable pancreatic cancer | I | Arm A- MEDI4736 + SBRT Arm B- Tremelimumab + SBRT Arm C-MEDI4736 + Tremelimumab + SBRT |
NCT02311361 |
| Tremelimumab + MEDI4736 | CTLA-4 inhibitor, PD-L1 inhibitor | 7 December 2015 | Recruiting | Advanced solid tumors (Urothelial bladder/ Triple negative Breast cancer/ PDAC) | II | Arm 1- Tremelimumab monotherapy Arm 2- MEDI4736 monotherapy Arm 3- Tremelimumab + MEDI4736 combination |
NCT02527434 |
| Tremelimumab + MEDI4736 + Mogamulizumab (anti- CCR-5) | CTLA-4 inhibitor, PD-L1 inhibitor, Anti chemokine receptor 5 | 4 December 2015 | Recruiting | Advanced solid tumors | I | Arm1- Mogamulizumab + MEDI4736 Arm2- Mogamulizumab + Tremelimumab |
NCT02301130 |